NAD+ Precursors and Cellular Aging: The State of the Evidence

Few areas of aging research have moved from the lab bench to the supplement aisle as quickly as NAD+ precursors. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are widely marketed with claims about energy, longevity, and "cellular youth." The underlying science is real and interesting. The human evidence, however, is far thinner than the marketing suggests. This article separates the two.

What NAD+ is and why researchers care

Nicotinamide adenine dinucleotide, usually written NAD+, is a coenzyme present in every living cell. Its classic role is in redox chemistry: it shuttles electrons in the reactions that turn nutrients into usable energy, including glycolysis and mitochondrial respiration.

Over the past two decades, researchers have found that NAD+ is also consumed as a substrate by several enzyme families, as summarized in reviews by Covarrubias and colleagues (2021) and Rajman and colleagues (2018):

• Sirtuins, a family of enzymes involved in regulating metabolism, stress responses, and gene expression.
• PARPs (poly ADP-ribose polymerases), which help repair damaged DNA.
• CD38 and related enzymes, which are involved in immune signaling and break down NAD+ and its precursors.

Because these enzymes consume NAD+ rather than just borrowing it, cells must constantly rebuild their supply. They do so mostly through a salvage pathway that recycles nicotinamide, with NMN as a key intermediate. NR sits one step further upstream and is converted to NMN inside cells.

The decline hypothesis

The central idea behind NAD+ research in aging is that tissue NAD+ levels fall with age, and that this decline contributes to age-related dysfunction. The evidence for the first half of that idea is strongest in rodents, where declines have been measured across multiple tissues. Human data exist but are more limited, rely on different measurement methods, and are not uniform across tissues (Covarrubias 2021).

Why levels fall is also an active question. One influential study by Camacho-Pereira and colleagues (2016) found that expression and activity of CD38 rise with age in mouse tissues, and that mice lacking CD38 were protected from age-related NAD+ decline and some associated mitochondrial dysfunction. The same study identified CD38 as a major enzyme breaking down NMN in the body, which matters for anyone designing precursor experiments. Increased consumption by PARPs responding to accumulating DNA damage is another proposed contributor.

The second half of the hypothesis, that the decline causes meaningful aging and that restoring NAD+ would reverse it, is where the evidence gets harder.

What the animal research shows

In rodents, the case for NAD+ precursors is fairly broad. Rajman and colleagues (2018) catalogued a large body of in vivo work in which raising NAD+ improved outcomes in models of metabolic disease, muscle aging, neurodegeneration, and more.

A frequently cited example is a year-long study by Mills and colleagues (2016). Normal chow-fed wild-type mice received NMN in their drinking water for 12 months, starting in young adulthood and continuing into middle age. Compared with controls, treated mice gained less weight with age, had better insulin sensitivity and lipid profiles, showed higher physical activity and energy metabolism, and had better eye function, with no obvious toxicity reported. Two co-authors were affiliated with a company that produces NMN, a detail visible in the paper's author list.

Animal studies like this are valuable for generating hypotheses. They are not evidence that the same effects occur in people. Mice differ from humans in metabolic rate, NAD+ turnover, and lifespan, and many interventions that extend healthspan in mice have not translated.

What human trials have shown

Human NAD+ precursor trials began appearing in the late 2010s. They share a common profile: small sample sizes, short durations, and a focus on safety and blood markers rather than clinical outcomes.

Safety and bioavailability

The most consistent finding is that oral NMN and NR are generally well tolerated in short trials and raise NAD+ or its metabolites in blood.

• Irie and colleagues (2020) gave single oral doses of NMN to 10 healthy men in a non-randomized study. No significant adverse clinical findings were reported over the observation period, and NMN metabolites in plasma rose in a dose-dependent way. Several co-authors were employed by a pharmaceutical company.
• Martens and colleagues (2018) ran a randomized, placebo-controlled crossover trial of NR in healthy middle-aged and older adults, with two six-week periods. NR was well tolerated and raised NAD+ in blood cells. The authors reported possible improvements in blood pressure and arterial stiffness in a subgroup, but framed these as signals for future trials to test, not established effects.

Tissue and functional effects

Showing that a precursor raises NAD+ in blood is only the first step. The harder question is whether it reaches target tissues and changes how they function.

• Muscle NAD+ in older men. Elhassan and colleagues (2019) gave NR or placebo to 12 older men for 21 days in a randomized crossover design. NR increased markers of the NAD+ metabolome in skeletal muscle and lowered several circulating inflammatory markers. It did not improve mitochondrial bioenergetics, which was one of the functions researchers had hoped to see change.
• Insulin sensitivity in prediabetic women. Yoshino and colleagues (2021) ran a 10-week randomized, double-blind, placebo-controlled trial of NMN in postmenopausal women with prediabetes and overweight or obesity. Using the gold-standard clamp technique, they found that insulin-stimulated glucose uptake in muscle improved with NMN but not with placebo, along with changes in muscle insulin signaling. It was a carefully designed study, but it was small, involved a narrow population, and measured one specific metabolic outcome.

Other small trials have reported mixed results on muscle function, walking performance, and metabolic markers, and several found no measurable change in the primary functional outcome. Taken together, the human literature supports a narrow claim: these compounds raise NAD+ metabolites, and in some settings they may modestly affect specific metabolic measures.

What has not been shown

It is just as important to be clear about what the research has not demonstrated:

1. No human trial has shown that NMN or NR slows biological aging.
2. No human trial has shown an effect on lifespan or on the incidence of age-related disease.
3. Long-term safety data in humans beyond months is limited.
4. It is not settled which tissues benefit, whether raising blood NAD+ reflects meaningful changes inside cells, or how much precursor is broken down before reaching target tissues.
5. Direct comparisons between NMN, NR, and NAD+ itself in humans are scarce, and studies giving NAD+ directly are fewer and smaller still.

There are also theoretical concerns that researchers continue to examine, such as whether boosting NAD+ could support the metabolism of senescent or cancerous cells in some contexts. These remain open questions rather than demonstrated risks, but they are one reason larger and longer trials matter.

Open research directions

The field is moving toward better-designed studies: larger samples, longer follow-up, pre-registered functional outcomes, and more precise measurement of NAD+ in tissues rather than blood alone. Researchers are also studying ways to reduce NAD+ breakdown, for example by inhibiting CD38, instead of simply adding more precursor.

For laboratory work with NAD+ and its precursors, material quality is a practical concern. These compounds can degrade with moisture, heat, and time, and supplement-grade products are not held to research standards. Our explainer on what makes a compound research grade and our guide to reading a certificate of analysis explain what identity and purity documentation should include.

The bottom line

NAD+ biology is a legitimate and productive area of aging research, with a strong mechanistic foundation and a broad base of animal data. The human evidence is early: small, short trials that confirm the precursors raise NAD+ metabolites and hint at specific metabolic effects. Anyone reading claims about reversing aging should hold them against that record.

Sources and further reading

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. doi.org/10.1038/s41580-020-00313-x
2. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. doi.org/10.1016/j.cmet.2018.02.011
3. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139. doi.org/10.1016/j.cmet.2016.05.006
4. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. doi.org/10.1016/j.cmet.2016.09.013
5. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi.org/10.1038/s41467-018-03421-7
6. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-1728. doi.org/10.1016/j.celrep.2019.07.043
7. Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. doi.org/10.1507/endocrj.EJ19-0313
8. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi.org/10.1126/science.abe9985

Peptrend.Health is an educational publication. Content on this site is for informational and research purposes only and is not medical advice, and it is not a substitute for guidance from a qualified professional. Products referenced from Prime Core Dynamics are sold for laboratory research use only and are not intended for human consumption.